Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Nature medicine - 1 Jul 2018

Mainardi Sara, Mulero-Sánchez Antonio, Prahallad Anirudh, Germano Giovanni, Bosma Astrid, Krimpenfort Paul, Lieftink Cor, Steinberg Jeffrey D, de Wit Niels, Gonçalves-Ribeiro Samuel, Nadal Ernest, Bardelli Alberto, Villanueva Alberto, Bernards Rene

Abstract excerpt

RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs)1-3. Inhibition of the RAS oncoproteins has proven difficult4, and attempts to target downstream effectors5-7 have been hampered by the activation of compensatory resistance mechanisms8. It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cellular Senescence

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Guanosine Triphosphate

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 29808006
DOI: 10.1038/s41591-018-0023-9

Genes

KRAS
BRAF
PTPN11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.PMID 29808006Read ↗

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.Semantic proximity Read ↗

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.Semantic proximity Read ↗

Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancersSemantic proximity Read ↗

PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.Semantic proximity Read ↗

Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.Semantic proximity Read ↗

Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesisSemantic proximity Read ↗

SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity.Semantic proximity Read ↗

BRAFV600E promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells.Semantic proximity Read ↗

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.Semantic proximity Read ↗

Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.